

Extensive Patient Data Facilitates the Development of Personalized Cancer Treatment Plans

Phil McNamara¹, Carolyn Brewster¹, Anna Lundberg¹, David Degnan¹, Jaclyn Smith², Kevin Matlock², Gans Srinivasa²

¹Bioinformatics & Genomics Masters Program, University of Oregon ²Omics Data Automation, Portland, OR

INTRODUCTION

Cancer is responsible for approximately 14.6% of all human deaths, and survivability is dependent on multiple factors which include age, genetics, disease progression, and health status at diagnosis^{1,2}. The interaction of these variables drives the uniqueness of each patient's cancer, complicating the choice of treatment.

Electronic health records (EHR) provide large amounts of medical data, which increase exponentially with modern automation.² EHR are designed for specific medical uses, and their format makes it difficult to ask meaningful research questions about the data. The creation of a database which relates all of this information together in a cleaned and standardized format will allow for exploration across multiple patients and types of data.

HYPOTHESIS

Extensive diagnostic, treatment, and demographic information for thousands of cancer patients organized in an intuitive, relational database can be used to research effective personalized cancer treatment plans.




WHY USE A RELATIONAL DATABASE?

Due to the export process, the data arrived in a disconnected and poorly-organized form. This dataset is particularly valuable because of the depth of information available for each patient. A **relational database** allows us to store the data in a modular format which still preserves interrelatedness.

The database structure enforces strict data types that allow users to ask complex questions based on the type of information involved. For example, a researcher could ask for the projected survival time based on patients' biological sex, BMI, number of surgeries, and white blood cell count. This kind of data exploration could also lead to the discovery of previously unknown risk factors.


GOALS

- Compile patient data into an intuitive relational database
 - Standardize data formats
 - Remove illogical typos
- Explore data to find trends
- Integrate with tissue images for more comprehensive and specific prediction



The PostgreSQL (version 10.5) database is hosted on a Red Hat Linux virtual machine at the University of Oregon.³ Tables are connected by subject ID.

THE DATABASE PATIENTS




PROPORTIONAL HAZARDS

- The Cox Proportional-Hazards model, a widely used regression analysis of survival data, estimates survivability based on predictors (called covariates).⁴
- This model assumes that hazard ratios do not change over time.
- This approach uses the date of a deceased patient's final datapoint as a proxy for time of death.

$$h(t) = h_0(t) \times e^{b_1x_1 + b_2x_2 + \dots + b_nx_n}$$

Survival Time, Baseline Hazard, Effect size, Covariate, Hazard ratios




FUTURE DIRECTIONS

- Expand database with additional patient data sets
- Integrate with machine learning tissue-imaging diagnostics
- Identify predictors of treatment response to facilitate “all in a day” development of personalized treatment plans

ACKNOWLEDGEMENTS

This project was made possible by the patients and families who shared their medical data for the benefit of others. We are grateful to Omics Data Automation and OHSU for their data, guidance, and support. We would also like to thank the BGMP and our mentors Stacey Wagner, Leslie Coonrod, Clay Small, Jason Sydes, and Pete Batzel for their input and expertise.



REFERENCES

1. Pavlopoulou, A., Spandidos, D., & Michalopoulos, I. (2014). Human cancer databases (review). *Oncology reports*, 33(1).
2. Miller, K., et al., (2016). Cancer treatment and survivorship statistics, 2016. *CA: a cancer journal for clinicians*, 66(4).
3. PostgreSQL Consortium. History. <https://www.postgresql.org/docs/10/biblio.html>. Accessed October 2018.
4. Singh, R., & Mukhopadhyay K. (2011). Survival analysis in clinical trials: basics and must know areas. *Perspectives in Clinical Research*, 2(4).

Code, poster, & supplementary materials available at git.io/fpQBf

